世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

B型インフルエンザ菌感染症: パイプラインレビュー 2016年下半期

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016

 

出版社 出版年月電子版価格 ページ数
Global Markets Direct
グローバルマーケッツダイレクト社
2016年10月US$2,000
シングルユーザライセンス
62

サマリー

Global Markets DirectによるB型インフルエンザ菌感染症のパイプラインレビューです。



Report Details

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape.

Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 4, 2, 3, 1 and 6 respectively for Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively for Haemophilus influenzae Type B Infections.

Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

目次

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Haemophilus influenzae Type B Infections Overview 8
Therapeutics Development 9
Pipeline Products for Haemophilus influenzae Type B Infections - Overview 9
Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis 10
Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies 11
Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes 12
Haemophilus influenzae Type B Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Haemophilus influenzae Type B Infections - Products under Development by Companies 16
Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes 18
Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development 19
Beijing Minhai Biotechnology Co., Ltd 19
Biological E. Limited 20
Daiichi Sankyo Company, Limited 21
Indian Immunologicals Limited 22
Kaketsuken K.K. 23
LG Life Science LTD. 24
Panacea Biotec Limited 25
Sanofi Pasteur SA 26
Sinovac Biotech Ltd. 27
Zydus Cadila Healthcare Limited 28
Haemophilus influenzae Type B Infections - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
(meningococcal + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Eupenta - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
haemophilus influenzae B vaccine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Haemophilus influenzae B vaccine - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Haemophilus influenzae B vaccine - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
hemophilus influenza [serotype B] vaccine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
KD-370 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
LT-Hib - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
NU-300 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
VN-0105 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Haemophilus influenzae Type B Infections - Dormant Projects 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る